iTeos Therapeutics
ITOS
ITOS was delisted on the 28th of August, 2025.
143 hedge funds and large institutions have $699M invested in iTeos Therapeutics in 2022 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 63 increasing their positions, 34 reducing their positions, and 28 closing their positions.
85% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 34
1.36% less ownership
Funds ownership: 104.5% → 103.14% (-1.4%)
6% less funds holding
Funds holding: 152 → 143 (-9)
9% less capital invested
Capital invested by funds: $768M → $699M (-$69M)
32% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 28
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$14M |
| 2 |
BlackRock
New York
|
+$13.7M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$10.7M |
| 4 |
Millennium Management
New York
|
+$9.53M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$4.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$16.9M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$13.4M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$12.9M |
| 4 |
State Street
Boston,
Massachusetts
|
-$8.53M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
-$5.52M |
ITOS Hedge Fund Activity: Q3 2022 in Review
143 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q3 2022, worth a combined $699M — down 9% from $768M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of ITOS and 19 opened new positions — a net loss of 9 holders — while 34 trimmed existing stakes and 63 added.
The largest buyer was Citadel Advisors, adding an estimated $14M. The largest seller was Rubric Capital Management (New York), exiting entirely with an estimated $16.9M sold.
- 143 institutional investors held iTeos Therapeutics (ITOS) as of Q3 2022, down from 152 in Q2 2022.
- Funds reported $699M of iTeos Therapeutics stock for Q3 2022, down 9% quarter-over-quarter.
- 19 funds opened new iTeos Therapeutics positions in Q3 2022 and 28 closed out, a net change of -9 holders.
- The largest iTeos Therapeutics buyer in Q3 2022 was Citadel Advisors, an estimated $14M added.
- The largest iTeos Therapeutics seller in Q3 2022 was Rubric Capital Management (New York), an estimated $16.9M sold.
Based on aggregated 13F filings for Q3 2022.